Synonym
Enloplatin; CL287,110; CL-287,110; CL 287,110
IUPAC/Chemical Name
Platinum, (1,1-cyclobutanedicarboxylato(2-))(tetrahydro-4H-pyran-4,4-dimethanamine-N,N')-, (SP-4-2)-
InChi Key
NAFFDQVVNWTDJD-UHFFFAOYSA-L
InChi Code
InChI=1S/C7H14N2O.C6H8O4.Pt/c8-5-7(6-9)1-3-10-4-2-7;7-4(8)6(5(9)10)2-1-3-6;/h8-9H,1-6H2;1-3H2,(H,7,8)(H,9,10);/q-2;;+4/p-2
SMILES Code
O=C1C2(C([O-][Pt+2]3([O-]1)NCC4(CN3)CCOCC4)=O)CCC2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
479.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kudelka AP, Siddik ZH, Tresukosol D, Edwards CL, Freedman RS, Madden TL, Rastogi R, Hord M, Kim EE, Tornos C, Mante R, Kavanagh JJ. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma. Anticancer Drugs. 1997 Aug;8(7):649-56. doi: 10.1097/00001813-199708000-00001. PMID: 9311439.
2: Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs. 1993 Sep;46(3):360-377. doi: 10.2165/00003495-199346030-00003. Erratum in: Drugs. 1993 Sep;46(3):377. PMID: 7693428.
3: Amorusi P, Lessard D, Bansal SK, Selinger K, Yacobi A, Tonelli AP. Analysis of enloplatin by liquid chromatography and of platinum by atomic absorption spectrometry in various biological fluids. J Pharm Biomed Anal. 1994 Aug;12(8):1023-33. doi: 10.1016/0731-7085(94)e0035-y. PMID: 7819376.
4: Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992 Dec 15;52(24):6885-9. PMID: 1458477.
5: Christian MC. The current status of new platinum analogs. Semin Oncol. 1992 Dec;19(6):720-33. PMID: 1462169.
6: CL 287,110 and CL 286,558. Cancer Invest. 1989;7(5):537. doi: 10.3109/07357908909041392. PMID: 2620257.
7: Bitha P, Carvajal SG, Citarella RV, Child RG, Delos Santos EF, Dunne TS, Durr FE, Hlavka JJ, Lang SA Jr, Lindsay HL, et al. Water-soluble third generation antitumor platinum complexes, [2,2-bis (aminomethyl)-1,3-propanediol-N,N']-[1,1-cyclobutanedicarboxylato (2-)-O,O']platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O'] [tetrahydro-4H-pyran-4,4-dimethanamine-N,N']platinum(II). J Med Chem. 1989 Aug;32(8):2015-20. doi: 10.1021/jm00128a052. PMID: 2754720.
